Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/s41392-020-0191-1 http://scihub22266oqcxt.onion/10.1038/s41392-020-0191-1 32467561!7255975!32467561     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 247.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Signal+Transduct+Target+Ther 2020 ; 5 (1): 84 Nephropedia Template TP {{tp|p=32467561|t=2020. Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 |pdf=|usr=}}{{32467561}} gab.com Text Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 JO: Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=32467561 #FOAvip To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called "cytokine storm", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages. Twit Text FOAVip Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 ????Signal Transduct Target Ther http://www.kidney.de/pget.php?&tw=1&pmid=32467561 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32467561 #FOAvip English Wikipedia <ref>{{Cite pmid|32467561}}</ref> Immune response in COVID-19: addressing a pharmacological challenge by targeting pathways triggered by SARS-CoV-2 #MMPMID32467561 Catanzaro M; Fagiani F; Racchi M; Corsini E; Govoni S; Lanni C Signal Transduct Target Ther 2020[May]; 5 (1): 84 PMID32467561show ga To date, no vaccines or effective drugs have been approved to prevent or treat COVID-19 and the current standard care relies on supportive treatments. Therefore, based on the fast and global spread of the virus, urgent investigations are warranted in order to develop preventive and therapeutic drugs. In this regard, treatments addressing the immunopathology of SARS-CoV-2 infection have become a major focus. Notably, while a rapid and well-coordinated immune response represents the first line of defense against viral infection, excessive inflammatory innate response and impaired adaptive host immune defense may lead to tissue damage both at the site of virus entry and at systemic level. Several studies highlight relevant changes occurring both in innate and adaptive immune system in COVID-19 patients. In particular, the massive cytokine and chemokine release, the so-called "cytokine storm", clearly reflects a widespread uncontrolled dysregulation of the host immune defense. Although the prospective of counteracting cytokine storm is compelling, a major limitation relies on the limited understanding of the immune signaling pathways triggered by SARS-CoV-2 infection. The identification of signaling pathways altered during viral infections may help to unravel the most relevant molecular cascades implicated in biological processes mediating viral infections and to unveil key molecular players that may be targeted. Thus, given the key role of the immune system in COVID-19, a deeper understanding of the mechanism behind the immune dysregulation might give us clues for the clinical management of the severe cases and for preventing the transition from mild to severe stages. |*Pandemics[MESH] |Adaptive Immunity/drug effects[MESH] |Angiotensin-Converting Enzyme 2[MESH] |Antiviral Agents/*therapeutic use[MESH] |Betacoronavirus/*drug effects/immunology/pathogenicity[MESH] |COVID-19[MESH] |Coronavirus Infections/*drug therapy/epidemiology/immunology/virology[MESH] |Cytokines/antagonists & inhibitors/genetics/immunology[MESH] |Disease Progression[MESH] |Gastrointestinal Microbiome/immunology[MESH] |Gene Expression Regulation[MESH] |Host-Pathogen Interactions/*drug effects/genetics/immunology[MESH] |Humans[MESH] |Immunity, Innate/drug effects[MESH] |Molecular Targeted Therapy[MESH] |Peptidyl-Dipeptidase A/genetics/immunology[MESH] |Pneumonia, Viral/*drug therapy/epidemiology/immunology/virology[MESH] |SARS-CoV-2[MESH] |Signal Transduction/*drug effects/genetics/immunology[MESH] |Spike Glycoprotein, Coronavirus/genetics/immunology[MESH] |T-Lymphocytes/drug effects/immunology/virology[MESH]Immune response in COVID-19: addressing a pharmacological challenge by(epmc).pdf DeepDyve Pubget Overpricing